Nuclidium: Betting on copper isotopes for scalable radiopharma supply chains

The demand for radiopharmaceuticals far exceeds current supply, with only a fraction of solid tumor patients able to access radioligand therapies. Nuclidium AG aims to close that gap by leveraging the unique features of copper-based isotopes to achieve scalable manufacturing of radioligand therapeutics and diagnostics.

To address the access problem, Swiss power plant Alpiq, one of Nuclidium’s early funders, recruited nuclear engineer Leila Jaafar-Thiel prior to the biotech’s founding; she’s now Nuclidium’s CEO. Drawing on her background in radionuclide production, she was tasked with identifying isotopes that could serve both therapeutic and diagnostic applications, or theranostics, while avoiding some of the manufacturing and supply constraints of other targeted radioligand therapies...